Skip to main content
 
HOME FOR INVENTORS FOR INDUSTRY FOR ENTREPRENEURS
 

Details

Project TitlePrevention and Treatment of Gastrointestinal Disorders
Track Code4153
Short Description

This invention introduces a method to treat and prevent necrotizing enterocolitis (NEC) in premature babies by orally administering branched chain fatty acids (BCFA)

Abstract

This invention introduces a method to treat and prevent necrotizing enterocolitis (NEC) in premature babies by orally administering branched chain fatty acids (BCFA). NEC, a life-threatening condition that affects 8-10% of premature infants, is caused by an overabundance of pathological bacteria in the gut. BCFA is possibly a necessary factor for normal gut development and an enhancer for the growth of gut friendly bacteria. Recent studies have demonstrated the positive effects of BCFA on the growth of probiotic organisms.

POTENTIAL APPLICATIONS:


  • The invention can be used to administer BCFA orally as a component of premature infant feeds to treat or prevent NEC.
  • BCFA can be included in therapeutics for conditions that involve microfloral colonization of the gastrointestinal tract. For example, BCFA can be used to maintain a healthy gut while on or after antibiotic treatments.
  • BCFA can also be used to treat inflammatory conditions involving the intestine, such as Inflammatory Bowel Disease (IBD).

ADVANTAGES:

Because BCFA are endogenous compounds, products derived from this technology will have few side effects, rendering this technology safe and low risk for all age groups. In addition, BCFA is resistant to gastric acidity, hydrolysis by mammalian enzymes, and gastrointestinal absorption.
 
Tagsdietary supplement, life science, food & dairy
 
Posted DateJul 20, 2012 7:54 PM

Researcher

Name
Rinat Ran-Ressler
James Brenna

Additional Information

None

Licensing Contact

Carolyn Theodore
607-254-4514
cat42@cornell.edu